Tesamorelin

Mechanism of action

Tesamorelin is structurally distinct from sermorelin and CJC-1295 in retaining the full 44-amino-acid sequence of native human GHRH rather than the 1-29 truncation. The protease-resistance modification is a single chemical addition — a trans-3-hexenoyl group covalently attached to the N-terminal tyrosine through an amide bond, replacing the unmodified N-terminal amine. This single modification blocks dipeptidyl peptidase-4 (DPP-4) cleavage at the otherwise-vulnerable His-Ala bond, extending the plasma half-life from approximately 5 minutes (native GHRH) to 26-38 minutes (tesamorelin). Mechanistically, tesamorelin functions as a full GHRH-receptor agonist with affinity comparable to native GHRH. Binding the GHRH receptor on anterior-pituitary somatotrophs activates the canonical Gαs/adenylate cyclase/cAMP/PKA cascade, triggering GH gene transcription and pulsatile release of stored GH. Released GH activates the JAK2/STAT5 pathway on hepatocytes and peripheral tissues, driving IGF-1 production and the downstream metabolic and tissue effects of GH-axis activation. The pharmacodynamic profile of once-daily tesamorelin produces sustained 24-hour IGF-1 elevation while preserving the underlying pulsatile GH-release pattern. The 26-38 minute plasma half-life is long enough to maintain meaningful GHRH-receptor stimulation through the dosing interval but short enough that pulsatility is not abolished — somatostatin tone restores between doses, and the diurnal nocturnal-peak pattern of physiological GH release is largely preserved. This positions tesamorelin pharmacologically between short-acting sermorelin (strictly pulsatile but logistically demanding) and DAC-modified CJC-1295 (sustained elevation with loss of pulsatility). The clinical efficacy that earned tesamorelin its FDA approval — selective reduction of visceral adipose tissue in HIV-associated lipodystrophy — is mediated by the GH-driven lipolytic activity that is amplified in pathologically expanded visceral fat depots. GH-axis activation increases hormone-sensitive lipase activity, suppresses lipoprotein lipase, and elevates circulating free fatty acid flux from adipose tissue, particularly from the metabolically active visceral depot. In HIV-lipodystrophy, which is characterised by paradoxical visceral fat accumulation despite peripheral fat loss, tesamorelin produced selective ~15-20% reductions in visceral adipose tissue volume (measured by CT scan) over 26 weeks of once-daily dosing in pivotal Phase III trials. A critical mechanistic feature distinguishing tesamorelin from chronic recombinant somatropin is the preserved IGF-1 negative-feedback architecture. Tesamorelin's pituitary-mediated GH release is subject to feedback suppression by elevated IGF-1, which prevents the supraphysiological GH/IGF-1 elevations seen with chronic exogenous somatropin. This physiological feedback architecture is the principal mechanistic argument for tesamorelin over somatropin in indications where modest, sustained GH-axis activation is desired.

Tesamorelin's once-daily subcutaneous dosing produces ~15-20% reduction of CT-measured visceral adipose tissue in HIV-associated lipodystrophy over 26 weeks (Falutz et al., AIDS, 2007; J Clin Endocrinol Metab, 2010), establishing the first FDA approval of any GHRH analogue and the first peptide therapy specifically licensed for a body-composition indication. The preserved pulsatile GH-release pattern under once-daily dosing distinguishes tesamorelin pharmacologically from chronic recombinant somatropin.

— Notable finding

Research history

Tesamorelin was developed by Theratechnologies (Montreal, Canada) as a stabilised GHRH analogue specifically for the treatment of HIV-associated lipodystrophy — the constellation of visceral fat accumulation, peripheral fat loss, dyslipidaemia, and insulin resistance that emerged as a major complication of combination antiretroviral therapy in the late 1990s and 2000s. The compound advanced through Phase II and Phase III development across the 2000s, with pivotal Phase III trials demonstrating selective reduction of CT-measured visceral adipose tissue and improvements in triglycerides, cholesterol, and quality-of-life measures in HIV-lipodystrophy patients. The FDA approved tesamorelin (Egrifta) in November 2010 for the indication 'reduction of excess abdominal fat in HIV-infected patients with lipodystrophy' — the only GHRH analogue to hold current FDA approval and one of very few peptide drugs marketed specifically for body-composition indications. Health Canada approval followed. The European Medicines Agency (EMA) Marketing Authorisation Application was withdrawn by Theratechnologies in 2014 after the CHMP rejected the application primarily because of the relatively small treatment effect compared to lifestyle modification and the lack of a clear survival or cardiovascular outcome benefit in HIV-lipodystrophy. Tesamorelin therefore holds FDA approval but no EU/UK marketing authorisation. A reformulated, more concentrated version (Egrifta SV) was approved by the FDA in 2019 to address some of the patient-experience limitations (large injection volume, multi-step daily reconstitution). The clinical-use population has remained small and predominantly United States-based given the regulatory geography. Research use of tesamorelin in the broader GH-axis literature outside the licensed indication has grown over the past decade, particularly in non-alcoholic fatty liver disease research (where the visceral-fat reduction has hepatic-fat correlates), in age-related GH decline, and in cognitive-decline research where tesamorelin's BBB-penetration profile has attracted attention. Several investigator-initiated trials have explored these off-label research applications. In the UK, tesamorelin is not available as a licensed medicine. Its FDA-approved status does not confer UK marketing authorisation. Specialist access through individual NHS funding requests or private importation under the unlicensed-medicines framework is theoretically possible but practically rare given the absence of UK licensing and the limited UK HIV-lipodystrophy population.

Reported research-model dose ranges

The ranges below are taken from published pre-clinical literature. They do not constitute a dosing recommendation for human use.

Summarised studies

Safety profile

Tesamorelin has the most extensive published clinical-trial safety dataset of any GH-axis peptide, accumulated through the pivotal Phase III HIV-lipodystrophy programme (multiple trials with combined enrolment >1,000 patients) and post-marketing surveillance since the 2010 FDA approval. The principal documented adverse events include injection-site reactions (erythema, pruritus, transient nodules — frequent but mild), arthralgia and peripheral oedema (~15-25%), paraesthesias (~10-15%), and the metabolic effects expected of GH-axis activation — modest insulin resistance with elevated fasting glucose and HbA1c in susceptible individuals. Fluid retention with peripheral oedema is the most consistent symptomatic adverse event of GH-axis activation, mediated by GH-driven renal sodium and water retention. In the tesamorelin Phase III programme, peripheral oedema was the most common adverse event leading to discontinuation, particularly in patients with pre-existing cardiac or renal disease. Joint pain (arthralgia), particularly in the small joints of the hands, reflects similar fluid-retention and connective-tissue effects of GH activation and is dose- and duration-dependent. The insulin resistance signal from tesamorelin is materially smaller than chronic recombinant somatropin given the preservation of the IGF-1 negative-feedback loop, but is non-zero. Fasting glucose and HbA1c rose modestly in the Phase III treated arms compared to placebo, and pre-existing diabetes is a recognised exacerbating factor. The FDA label requires glucose monitoring during chronic tesamorelin therapy. The theoretical oncology concerns common to GH-axis activation — sustained IGF-1 elevation theoretically increasing IGF-1R-driven tumour growth — were addressed in the Phase III programme with cancer-related exclusion criteria. Post-marketing surveillance has not identified a clear cancer signal, though the dataset duration is limited to ~15 years since approval. Active malignancy and recent cancer history remain FDA-label contraindications. Anti-tesamorelin antibodies develop in approximately 50% of chronically treated patients but are generally not neutralising and have not been associated with documented loss of efficacy or with hypersensitivity reactions. Acute hypersensitivity reactions including rare reports of acute pancreatitis exist in post-marketing data and are reflected in the FDA label. Serious adverse events specifically attributable to tesamorelin (excluding events related to the underlying HIV disease) have been uncommon. The overall safety record is the strongest of the GH-axis peptide class and reflects the relatively conservative IGF-1 elevation produced by tesamorelin's pulsatile-preserving mechanism.

UK regulatory status

Tesamorelin is not authorised as a medicinal product by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and holds no UK marketing authorisation. The Theratechnologies EMA marketing authorisation application was withdrawn in 2014, so the compound has no European Union licensing position to inherit. It is not a controlled substance under the Misuse of Drugs Act 1971. Tesamorelin holds current FDA approval (Egrifta and Egrifta SV) for HIV-associated lipodystrophy in the United States. This FDA approval does not confer UK marketing authorisation. Specialist access for individual UK patients with HIV-associated lipodystrophy through the unlicensed-medicines framework (Regulation 167 of the Human Medicines Regulations 2012, the 'specials' route) is theoretically possible via a named prescriber and an importation arrangement, but is rarely pursued in practice given the limited UK lipodystrophy population and the cost of imported specialist medicines. Tesamorelin is captured by the World Anti-Doping Agency (WADA) Prohibited List under category S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) as a growth-hormone-releasing hormone analogue. Athletes subject to anti-doping testing should treat tesamorelin as prohibited both in-competition and out-of-competition regardless of claimed research or therapeutic purpose. Research-grade tesamorelin for in-vitro and animal research is available from research-chemical suppliers; possession for bona fide laboratory research is generally unrestricted in the UK. Supply for human use outside an authorised clinical-trial framework or specials importation engages the Human Medicines Regulations 2012 and is generally an offence. For animal research under ASPA, tesamorelin requires standard project and personal licences.

Frequently asked questions